Muscular Dystrophy Trial, Recruiting (NCT07630389)

Muscular Dystrophy Trial, Recruiting NCT07630389 Sponsor: University of Rochester Condition: Muscular Dystrophy

Printed from Voxsanity (voxsanity.com.au) — NCT07630389 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Muscular Dystrophy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The child or young person must be between 0 and 17 years old
They must have been diagnosed with congenital, childhood, or juvenile myotonic dystrophy type 1 (DM1, a specific inherited muscle condition)
The child and/or their parent or guardian must be able to speak English
A parent or guardian must be willing to give their permission for the child to take part
If the child is old enough and able to understand, they should also be willing to agree to take part themselves
The family must have access to wifi at home

Who may not be able to join:

Children who have another medical condition (besides DM1), such as another muscle or nerve disorder, cerebral palsy, or another condition affecting the brain or nervous system, that the study doctors think could affect the results
Children who have had a significant injury or accident shortly before the study visit that could affect how they move or function (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Johanna Hamel, MD, University of Rochester

Phone: 585-275-0420

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07630389

Sponsor: University of Rochester

Phase: Not Applicable

Status: Recruiting

Condition: Muscular Dystrophy

Trial contact: 585-275-0420

More information: https://clinicaltrials.gov/study/NCT07630389

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The child or young person must be between 0 and 17 years old
They must have been diagnosed with congenital, childhood, or juvenile myotonic dystrophy type 1 (DM1, a specific inherited muscle condition)
The child and/or their parent or guardian must be able to speak English
A parent or guardian must be willing to give their permission for the child to take part
If the child is old enough and able to understand, they should also be willing to agree to take part themselves
The family must have access to wifi at home

Who may not be able to join:

Children who have another medical condition (besides DM1), such as another muscle or nerve disorder, cerebral palsy, or another condition affecting the brain or nervous system, that the study doctors think could affect the results
Children who have had a significant injury or accident shortly before the study visit that could affect how they move or function (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

University of Rochester

Registry

ClinicalTrials.gov

Start date

13 November 2023

Est. completion

1 January 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Remote assessment of cognitive function; Remote assessment of grip strength; Remote assessment of Video Hand Opening Time (VHOT); 10 Meter Walk/Run Test; Genetic Test; Remote assessment of activity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov